Akari Therapeutics, Plc

Equities

AKTX

US00972G2075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-06-14 pm EDT 5-day change 1st Jan Change
3.16 USD +3.61% Intraday chart for Akari Therapeutics, Plc +41.70% +1.28%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
European Equities Traded in the US as American Depositary Receipts Sharply Lower in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading MT
Tech Firms Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
Akari Therapeutics, plc Appoints Samir R. Patel as Interim President CI
European Equities Traded in the US as American Depositary Receipts Trend Lower in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading MT
European Equities Traded in US as American Depositary Receipts Rise Friday, Poised to End Week Lower MT
Akari Therapeutics, Plc announced that it has received $14.392174 million in funding CI
Akari Therapeutics, Plc announced that it expects to receive $15.192172 million in funding CI
European Equities Traded in the US as American Depositary Receipts Trend Higher Friday, End Week Marginally Lower MT
Tech Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Marginally Higher in Monday Trading MT
Akari Therapeutics, Plc announced that it has received $0.5 million in funding CI
Akari Therapeutics, Plc Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading; End Week Up Nearly 3% MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
Akari Therapeutics, plc Announces the Resignation of Rachelle Jacques from the Board of Directors CI
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower MT
European Equities Traded in the US as American Depositary Receipts Rise Modestly Higher in Thursday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
Akari Therapeutics, Plc Announces CEO Changes CI
Melissa Bradford-Klug to Step Down as Chief Operating Officer of Akari Therapeutics, Plc CI
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading MT
Chart Akari Therapeutics, Plc
More charts
Akari Therapeutics, Plc is a late-stage biotechnology company. The Company is developing advanced therapies for autoimmune and inflammatory diseases. Its lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Its pipeline includes a Phase 3 clinical trial program investigating nomacopan for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). It is conducting a clinical trial of subcutaneous nomacopan for the treatment of HSCT-TMA in pediatrics. The United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease, Orphan Drug, and Fast Track designations to nomacopan for the treatment of pediatric HSCT-TMA. It is also investigating long-acting PASylated-nomacopan (PAS-nomacopan) for treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (dry AMD) in preclinical studies.
More about the company
  1. Stock Market
  2. Equities
  3. AKTX Stock
  4. News Akari Therapeutics, Plc
  5. European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading